{"id":469143,"date":"2025-09-22T00:00:00","date_gmt":"2025-09-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2025-biopharma-type-1-diabetes-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:25:04","modified_gmt":"2026-03-31T10:25:04","slug":"dlsfmd0009-2025-biopharma-type-1-diabetes-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0009-2025-biopharma-type-1-diabetes-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Type 1 Diabetes &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The treatment options for type 1 diabetes (<abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr>) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (<abbr data-abbreviation-entity=\"10361\" title=\"sodium-glucose co-transporter\">SGLT<\/abbr>-2) inhibitors (only in Japan) are the only approved therapies. The launch of Sanofi \/ Provention Bio\u2019s novel disease-modifying therapy teplizumab (Tzield) and Novo Nordisk\u2019s first-in-class weekly insulin icodec (Awiqli) represents significant advancements in the <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> market. There is a substantial unmet need for disease-modifying therapies that could enhance the long-term outcomes for <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> patients. Emerging therapies, such as pancreatic beta-cell replacement therapies and CD3 antigen inhibitors, are being investigated for their potential effectiveness in newly diagnosed patients, aiming to slow the progression of <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers and constraints in the <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> market and how will the market evolve over the forecast period?<\/li>\n<li>What impact will the launch of Novo Nordisk\u2019s insulin icodec (Awiqli) have on daily basal insulins and the overall use of insulin analogues?<\/li>\n<li>What is the impact of the launch of Sanofi \/ Provention Bio\u2019s teplizumab (Tzield) on insulins and the overall approach to managing <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr>?<\/li>\n<li>How are biosimilar insulins being adopted and how will they impact the overall <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> market?<\/li>\n<li>What changes will the increasing use of insulin pumps bring to market dynamics?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research: <\/strong>Country-specific interviews with thought-leading endocrinologists and diabetologists. Survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology: <\/strong>Diagnosed prevalence of <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> by country and drug-treated rates.<\/li>\n<li><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> therapies through 2034, segmented by brands \/ generics and subpopulations.<\/li>\n<li><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<div>\n<p style=\"\">Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW76556118 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW76556118 BCX0 round-bullets\">\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW76556118 BCX0 round-bullets\">\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW76556118 BCX0 round-bullets\">\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"template":"","class_list":["post-469143","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469143\/revisions"}],"predecessor-version":[{"id":575736,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469143\/revisions\/575736"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=469143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}